The prevention of atherothrombotic
events (cardiovascular (CV) death, myocardial infarction (MI) or stroke) after an acute coronary syndrome in adult patients with elevated cardiac biomarkers and no prior stroke or transient ischaemic attack (TIA) when co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine
The use of an antiplatelet agent after PCI reduces the risk of ischaemic or atherothrombotic
events(8) but raises the risk of bleeding".
Brilinta, co-administered with aspirin, is indicated for the prevention of atherothrombotic
events in adult patients with ACS, or for patients with a history of MI and a high risk of developing an atherothrombotic
Reducing platelet activity with aspirin and other antiplatelet agents is an important factor in the prevention and management of atherothrombotic
vascular events.1 For this indication, aspirin has both beneficial and potentially harmful effects; it can diminish or reverse thrombus formation (eg, in the setting of acute myocardial infarction or stroke), but it also increases the risk of bleeding.
Patients with PAD are at the higher risk for major atherothrombotic
events such as stroke and myocardial infarction.
Interplay between ultrastructural findings and atherothrombotic
complications in type 2 diabetes mellitus.
To the Editor: Hyperhomocysteinemia (HHcy) is an important risk factor for atherothrombotic
disease and venous thrombosis. Normally, homocysteine (Hcy) is either remethylated to methionine (Met) by a Vitamin B12-dependent reaction or betaine as the methyl donor, or trans-sulfurated to cysteine through a pyridoxine-dependent reaction.
The European Commission has approved a combination of Bayer Pharmaceuticals' Xarelto (rivaroxaban) 2.5mg twice daily and low dose aspirin (acetylsalicylic acid/ASA) once daily for the prevention of atherothrombotic
events in adult patients with coronary artery disease or symptomatic peripheral arterial disease at high risk of ischaemic events, it was reported yesterday.
cerebral infarction is the most common subtype of cerebral infarctions, having an approximate frequency of 37%2 being the clinical consequence of the atheromatous disease.
In the vast majority of cases, its cause comes from atherosclerotic and atherothrombotic
phenomena, but may also reflect the influence of other diseases, such as diabetes, high blood pressure, and high blood cholesterol (9,14).
Hacke et al., "Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic
events," New England Journal of Medicine, vol.
The previous study from our group has also demonstrated that elevated homocysteine correlated with severity and prognosis in patients with atherothrombotic